NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 910 DKK | +0.01% |
|
+3.10% | +30.35% |
| 06:04pm | Novo Nordisk's Wegovy Reduces Cardiac Events, Sustains Weight Loss, New Analysis Shows | MT |
| 04:34pm | Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 29TCr 4.2TCr 3,50400Cr | Sales 2025 * | 35TCr 5.06TCr 4,22600Cr | Capitalization | 4,05300Cr 59TCr 49,06300Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 10TCr 1.51TCr 1,26000Cr | Net income 2025 * | 13TCr 1.84TCr 1,53300Cr | EV / Sales 2024 * | 14 x |
| Net Debt 2024 * | 1.33TCr 193.37Cr 16TCr | Net cash position 2025 * | 1.26TCr 183.14Cr 15TCr | EV / Sales 2025 * | 11.6 x |
| P/E ratio 2024 * |
39.2
x | P/E ratio 2025 * |
32.1
x | Employees | 66,015 |
| Yield 2024 * |
1.3% | Yield 2025 * |
1.56% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
| 1 day | +0.01% | ||
| 1 week | +3.10% | ||
| Current month | +0.82% | ||
| 1 month | +3.50% | ||
| 3 months | +7.45% | ||
| 6 months | +33.27% | ||
| Current year | +30.35% |
1 week
881.60
927.00
1 month
826.70927.00
Current year
688.80932.00
1 year
504.40932.00
3 years
237.73932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 01/91/01 | |
| Director of Finance/CFO | 53 | 01/99/01 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 19/15/19 |
Helge Lund
CHM | Chairman | 61 | 23/17/23 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/18/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +17.77% | ||
| 10.45% | 5 M€ | +12.31% | ||
| 5.40% | 17 M€ | +6.46% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 910 | +0.01% | 3 118 148 |
| 13/24/13 | 909.9 | +3.02% | 4,150,455 |
| 08/24/08 | 883.2 | +0.07% | 2,737,492 |
| 07/24/07 | 882.6 | +3.66% | 9,320,634 |
Delayed Quote Nasdaq Copenhagen, May 14, 2024 at 08:29 pm IST
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
909.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.35% | 59TCr | |
| +29.52% | 68TCr | |
| -3.75% | 36TCr | |
| +17.72% | 33TCr | |
| +3.28% | 28TCr | |
| +15.53% | 24TCr | |
| +10.16% | 21TCr | |
| -8.14% | 20TCr | |
| +7.38% | 17TCr | |
| -2.01% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock